STAM™ Mice Is The Best NASH model For Microbiome Therapeutics Study

We are pleased to introduce the development of drugs for non-alcoholic steatohepatitis (NASH) focusing on the gut microbiome and overview of studies using our STAM™ mice.


Currently, the development of treatment and prevention methods for various diseases targeting the gut microbiome is progressing around the world.

The relationship between NASH and the gut microbiome, such as increased intestinal permeability and dysbiosis, is getting elucidated [1-3]. For this reason, a microbiome-based therapy approach to treating Non-alcoholic steatohepatitis (NASH) is gathering attention.


Guoxiang et al. reported that in STAM™ mice, changes in the gut microbiome, such as increases in Bacteroides and Clostridium in the gut, occurred, which correlated with increases in blood and liver LPS levels and NAFLD Activity Score. These changes in the gut microbiome have also been observed in human NASH [4, 5]


Several studies in STAM™ mice to evaluate microbiome therapeutics for NASH are listed below:

■Tsumura & Co. (JPN) has reported improved NAFLD activity score and gut microbiota diversity in STAM™ mice treated with Kampo medocone Daisaikoto. They also discovered that changes in those gut microbiome correlated with NASH pathogenesis in STAM™ mice.

Learn more ► Ishizawa S et al., Gene. 2022

■MRM Health NV (BEL) has reported that the NAFLD activity score and Sirius Red positive area and CK-18 level, a biomarker for NASH, are significantly reduced in STAM™ mice treated with a bacterial consortium composed of nine human gut commensal strains.

Learn more ► Pinheiro I et al., Biomedicines. 2022

■GN Corporation Co. Ltd. (JPN) has reported improved NAFLD activity score and Sirius Red positive area and gut microbiota diversity in STAM™ mice treated with two types of β-glucan.

Learn more ► Ikewaki N et al., J Clin Exp Hepatol. 2022; Preethy S et al., BMJ Open Gastroenterol. 2022


From the above, the STAM™ mouse is an optimal pathological model mouse for the development of NASH therapeutics focusing on the gut microbiome.


If you have a NASH/NAFLD-related drug development or research project focused on gut bacteria, we recommend that you consider in vivo studies using STAM™ mice.


If you have any interest or questions, please feel free to contact us.



  1. Zhu L et al., Hepatology. 2013
  2. Luther J, et al. Cell Mol Gastroenterol Hepatol. 2015
  3. Tsay CJ, et al. Clin Liver Dis (Hoboken). 2022
  4. Kolodziejczyk AA, et al. EMBO Mol Med. 2019
  5. Sharpton SR, et al. Clin Gastroenterol Hepatol. 2019


■About STAM™ mice

■About NAFLD Activity Score